Glucagon-like peptide-1 (GLP-1) analoga and inhibitors of dipeptidyl peptidase-IV (DPP-IV) are current new treatment options for patients with type 2 diabetes mellitus, a high-risk population for atherosclerosis [1], [2], [3]. The gene discussed is DPP4; the disease is diabetes mellitus.